Celiac disease screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Usama Talib (talk | contribs) No edit summary |
||
| Line 15: | Line 15: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | [[Category:Gastroenterology]] | ||
[[Category:Primary care]] | |||
[[Category:Rheumatology]] | |||
[[Category:Autoimmune diseases]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Genetic disorders]] | |||
[[Category:Malnutrition]] | |||
[[Category:Pediatrics]] | |||
[[Category:Dermatology]] | |||
[[Category:Primary care]] | |||
[[Category:Up-To-Date]] | |||
Revision as of 14:46, 12 September 2017
|
Celiac disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Celiac disease screening On the Web |
|
American Roentgen Ray Society Images of Celiac disease screening |
|
Risk calculators and risk factors for Celiac disease screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
Screening with tissue transglutaminase (tTG) IgA test is recommended for symptomatic high risk patients.
Screening
- Screening in asymptomatic persons is not recommended.[1]
- Screening is recommended for symptomatic and high risk patients with positive family history in first and second degree relatives also in patients with other autoimmune diseases such as, type 1 diabetes mellitus, inflammatory luminal gastrointestinal disorders, Down syndrome, Turner syndrome, IgA deficiency, and IgA nephropathy.[1]
- Screening method for celiac disease is tissue transglutaminase (tTG) IgA test.